Nitesh Sanghai

Nitesh is a first-generation scientist and the 2025 Mitacs Innovation Award recipient for Outstanding Innovation at the University of Manitoba, Canada. He earned his Ph.D. in medicinal chemistry and neuroscience under Dr. Geoffrey K. Tranmer, during which he co-invented a first-in-class therapeutic candidate with the potential to slow the progression of incurable amyotrophic lateral sclerosis (ALS). Driven to translate discovery into impact, Nitesh and Dr. Tranmer cofounded Borotherapeutics Ltd., advancing Borsantrazole™ toward clinical development. He is currently a postdoctoral fellow in Dr. Tranmer’s laboratory, focused on translating Borsantrazole from bench to the bedside of ALS patients. Committed to community-engaged research, Nitesh collaborates with ALS organizations worldwide, dedicating his career to delivering hope for patients facing this devastating disease. His work bridges science, entrepreneurship, and patient-centered innovation across disciplines globally.